Literature DB >> 27142047

Severe Cardiomyopathy as the Isolated Presenting Feature in an Adult with Late-Onset Pompe Disease: A Case Report.

Mari Mori1, Lauren A Bailey2, Januario Estrada3, Catherine W Rehder3, Jennifer S Li4, Joseph G Rogers5, Deeksha S Bali2, Anne F Buckley3, Priya S Kishnani2.   

Abstract

Many inborn errors of metabolism can cause cardiomyopathy. Cardiomyopathy associated with glycogen storage includes PRKAG2-associated glycogen storage disease (GSD), Danon disease, infantile-onset Pompe disease (GSD II), GSD III, GSD IV, and phosphofructokinase deficiency (Tarui disease or GSD VII).We present a 35-year-old female who presented with cardiomyopathy after a pregnancy complicated by primary hyperparathyroidism. She had enjoyed excellent health until her first pregnancy at age 33. One week postpartum, she developed dyspnea and an echocardiogram revealed left ventricular ejection fraction (LVEF) of 35%. A cardiac MRI was consistent with nonischemic cardiomyopathy with an infiltrative process. Endomyocardial biopsy showed striking sarcoplasmic vacuolization, excess glycogen by PAS staining, and frequent membrane-bound glycogen by electron microscopy, consistent with lysosomal GSD. Acid alpha-glucosidase (GAA) activity in skin fibroblasts was in the affected range for Pompe disease. Sequencing of the GAA gene revealed a paternally inherited pathogenic c.525delT (p.Glu176Argfs*45) and a de novo c.309C>G (p.Cys103Trp) with unknown pathogenicity. Testing of the familial mutations in her daughter indicated that the variants in the proband were in trans. 26-gene cardiomyopathy sequencing panel had normal results thereby excluding GSD III, Danon disease, Fabry disease, and PRKAG2-associated cardiomyopathy. Therefore, results strongly suggest a diagnosis of Pompe disease.Pompe disease has a broad disease spectrum, including infantile-onset (IOPD) and late-onset (LOPD) forms. LOPD typically presents with proximal muscle weakness and respiratory insufficiency in childhood or late adulthood. Our case may represent a very unusual presentation of adult LOPD with isolated cardiomyopathy without skeletal muscle involvement or respiratory failure.

Entities:  

Keywords:  Acid phosphatase; Cardiomyopathy; Electron microscopy; Hypertrophic; Membrane-bound; Pompe disease (glycogen storage disease type II); Vacuolation

Year:  2016        PMID: 27142047      PMCID: PMC5388642          DOI: 10.1007/8904_2016_563

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  15 in total

1.  The Mount Sinai Hospital clinicalpathological conference: a 45-year-old man with Pompe's disease and dilated cardiomyopathy.

Authors:  R Ben-Ami; J Puglisi; T Haider; D Mehta
Journal:  Mt Sinai J Med       Date:  2001-05

2.  Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD type VII).

Authors:  Olimpia Musumeci; Claudio Bruno; Tiziana Mongini; Carmelo Rodolico; M'hammed Aguennouz; Emanuele Barca; Angela Amati; Denise Cassandrini; Luigi Serlenga; Giuseppe Vita; Antonio Toscano
Journal:  Neuromuscul Disord       Date:  2011-11-30       Impact factor: 4.296

3.  Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease).

Authors:  I Nishino; J Fu; K Tanji; T Yamada; S Shimojo; T Koori; M Mora; J E Riggs; S J Oh; Y Koga; C M Sue; A Yamamoto; N Murakami; S Shanske; E Byrne; E Bonilla; I Nonaka; S DiMauro; M Hirano
Journal:  Nature       Date:  2000-08-24       Impact factor: 49.962

4.  Hypertrophic cardiomyopathy due to the mitochondrial DNA mutation m.3303C>T diagnosed in an adult male.

Authors:  Tomas Palecek; Marketa Tesarova; Petr Kuchynka; Vladimir Dytrych; Milan Elleder; Helena Hulkova; Hana Hansikova; Tomas Honzik; Jiří Zeman; Ales Linhart
Journal:  Int Heart J       Date:  2012       Impact factor: 1.862

Review 5.  Primary hyperparathyroidism and heart disease--a review.

Authors:  Patrik Andersson; Erik Rydberg; Ronnie Willenheimer
Journal:  Eur Heart J       Date:  2004-10       Impact factor: 29.983

6.  Hypertrophic cardiomyopathy in pompe disease is not limited to the classic infantile-onset phenotype.

Authors:  Dong-Hwan Lee; Wen-Juan Qiu; Jeongho Lee; Yin-Hsiu Chien; Wuh-Liang Hwu
Journal:  JIMD Rep       Date:  2014-09-12

7.  Cardiac involvement in adults with Pompe disease.

Authors:  O I I Soliman; N A M E van der Beek; P A van Doorn; W B Vletter; A Nemes; B M Van Dalen; F J ten Cate; A T van der Ploeg; M L Geleijnse
Journal:  J Intern Med       Date:  2008-04-04       Impact factor: 8.989

8.  Glycogen storage disease type III diagnosis and management guidelines.

Authors:  Priya S Kishnani; Stephanie L Austin; Pamela Arn; Deeksha S Bali; Anne Boney; Laura E Case; Wendy K Chung; Dev M Desai; Areeg El-Gharbawy; Ronald Haller; G Peter A Smit; Alastair D Smith; Lisa D Hobson-Webb; Stephanie Burns Wechsler; David A Weinstein; Michael S Watson
Journal:  Genet Med       Date:  2010-07       Impact factor: 8.822

9.  Pompe disease diagnosis and management guideline.

Authors:  Priya S Kishnani; Robert D Steiner; Deeksha Bali; Kenneth Berger; Barry J Byrne; Laura E Case; Laura Case; John F Crowley; Steven Downs; R Rodney Howell; Richard M Kravitz; Joanne Mackey; Deborah Marsden; Anna Maria Martins; David S Millington; Marc Nicolino; Gwen O'Grady; Marc C Patterson; David M Rapoport; Alfred Slonim; Carolyn T Spencer; Cynthia J Tifft; Michael S Watson
Journal:  Genet Med       Date:  2006-05       Impact factor: 8.822

10.  Clinical and genetic heterogeneity of branching enzyme deficiency (glycogenosis type IV).

Authors:  C Bruno; O P van Diggelen; D Cassandrini; M Gimpelev; B Giuffrè; M A Donati; P Introvini; A Alegria; S Assereto; L Morandi; M Mora; E Tonoli; S Mascelli; M Traverso; E Pasquini; M Bado; L Vilarinho; G van Noort; F Mosca; S DiMauro; F Zara; C Minetti
Journal:  Neurology       Date:  2004-09-28       Impact factor: 9.910

View more
  3 in total

1.  Expansion of immature, nucleated red blood cells by transient low-dose methotrexate immune tolerance induction in mice.

Authors:  J Q Tran; D Grover; M Zhang; M Stapels; R Brennan; D S Bangari; P A Piepenhagen; E Roberts; P Oliva; F Zubair; J L Vela; S M Richards; A M Joseph
Journal:  Clin Exp Immunol       Date:  2020-12-16       Impact factor: 5.732

2.  Patients with glycogen storage diseases undergoing anesthesia: a case series.

Authors:  Carmelina Gurrieri; Juraj Sprung; Toby N Weingarten; Mary E Warner
Journal:  BMC Anesthesiol       Date:  2017-10-06       Impact factor: 2.217

3.  Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease-associated variants, common sequence variants, and results from newborn screening.

Authors:  Douglas O S de Faria; Stijn L M In 't Groen; Marianne Hoogeveen-Westerveld; Monica Y Nino; Ans T van der Ploeg; Atze J Bergsma; W W M Pim Pijnappel
Journal:  Hum Mutat       Date:  2020-12-21       Impact factor: 4.878

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.